Amir Ashoorzadeh

University of Auckland

New Zealand

Research Interests

Explore related searches

Professors in New Zealand

Contact this professor

ORCID

Google Scholar

Articles (9)

The dinitrobenzamide mustard prodrugs, PR-104A and SN27686, for use in a novel MNDEPT cancer prodrug therapy approach

Article Link

Year:

2023

Interrogation of the Structure–Activity Relationship of a Lipophilic Nitroaromatic Prodrug Series Designed for Cancer Gene Therapy Applications

Article Link

Year:

2022

Bioreductive prodrug PR-104 improves the tumour distribution and titre of the nitroreductase-armed oncolytic adenovirus ONYX-411NTR leading to therapeutic benefit

Article Link

Year:

2022

Tissue Pharmacokinetic Properties and Bystander Potential of Hypoxia-Activated Prodrug CP-506 by Agent-Based Modelling

Article Link

Year:

2022

Selectively Targeting Tumor Hypoxia with the Hypoxia-Activated Prodrug CP-506

Article Link

Year:

2021

Use of an optimised enzyme/prodrug combination for Clostridia directed enzyme prodrug therapy induces a significant growth delay in necrotic tumours.

Article Link

Year:

2021

Restoring Tumour Selectivity of the Bioreductive Prodrug PR-104 by Developing an Analogue Resistant to Aerobic Metabolism by Human Aldo-Keto Reductase 1C3

Article Link

Year:

2021

Directed evolution of the B. subtilis nitroreductase YfkO improves activation of the PET-capable probe SN33623 and CB1954 prodrug

Article Link

Year:

2021

E. coli nitroreductase NfsA is a reporter gene for non-invasive PET imaging in cancer gene therapy applications

Article Link

Year:

2020

Collaborators (5)

David Ackerley

Professor and Programme Director, Biotechnology

Victoria University of Wellington

NEW ZEALAND

Chris Gwenin

Abertay University

UNITED KINGDOM

Anna Wolfram

University of Tübingen

GERMANY

Adam Patterson

Associate Professor

University of Auckland

NEW ZEALAND

Jan Theys

University of Maastricht

NETHERLANDS

Amir Ashoorzadeh

Research Interests

Explore related searches

Contact this professor

Articles (9)

The dinitrobenzamide mustard prodrugs, PR-104A and SN27686, for use in a novel MNDEPT cancer prodrug therapy approach

Interrogation of the Structure–Activity Relationship of a Lipophilic Nitroaromatic Prodrug Series Designed for Cancer Gene Therapy Applications

Bioreductive prodrug PR-104 improves the tumour distribution and titre of the nitroreductase-armed oncolytic adenovirus ONYX-411NTR leading to therapeutic benefit

Tissue Pharmacokinetic Properties and Bystander Potential of Hypoxia-Activated Prodrug CP-506 by Agent-Based Modelling

Selectively Targeting Tumor Hypoxia with the Hypoxia-Activated Prodrug CP-506

Use of an optimised enzyme/prodrug combination for Clostridia directed enzyme prodrug therapy induces a significant growth delay in necrotic tumours.

Restoring Tumour Selectivity of the Bioreductive Prodrug PR-104 by Developing an Analogue Resistant to Aerobic Metabolism by Human Aldo-Keto Reductase 1C3

Directed evolution of the B. subtilis nitroreductase YfkO improves activation of the PET-capable probe SN33623 and CB1954 prodrug

E. coli nitroreductase NfsA is a reporter gene for non-invasive PET imaging in cancer gene therapy applications

Collaborators (5)

David Ackerley

Chris Gwenin

Anna Wolfram

Adam Patterson

Jan Theys

How do I reach out?

Meet Kite AI